300122 智飞生物
已收盘 03-20 15:00:00
资讯
新帖
简况
智飞生物：公司与中山大学、中山大学肿瘤防治中心就EB病毒候选疫苗产品的开发达成合作
证券之星 · 16:45
智飞生物：公司与中山大学、中山大学肿瘤防治中心就EB病毒候选疫苗产品的开发达成合作
智飞生物（300122）披露控股股东部分股份质押公告，3月17日股价下跌0.73%
证券之星 · 03-17
智飞生物（300122）披露控股股东部分股份质押公告，3月17日股价下跌0.73%
智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗获临床试验批准
智通财经 · 03-16
智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗获临床试验批准
智飞生物：截至2026年3月10日，公司普通股股东人数为123603
证券之星 · 03-13
智飞生物：截至2026年3月10日，公司普通股股东人数为123603
智飞生物：宸安生物的司美格鲁肽注射液（减重）已完成临床III期患者入组
证券之星 · 03-13
智飞生物：宸安生物的司美格鲁肽注射液（减重）已完成临床III期患者入组
“真金白银”显诚意：代表委员热议如何增强投资者“获得感”
21世纪经济报道 · 03-06
“真金白银”显诚意：代表委员热议如何增强投资者“获得感”
智飞生物：人二倍体狂犬病疫苗、15价肺炎结合疫苗、四价流脑结合疫苗、利拉鲁肽注射液、德谷胰岛素注射液处于申报上市阶段
证券之星 · 03-06
智飞生物：人二倍体狂犬病疫苗、15价肺炎结合疫苗、四价流脑结合疫苗、利拉鲁肽注射液、德谷胰岛素注射液处于申报上市阶段
智飞生物(300122.SZ)：德谷胰岛素注射液申请生产注册获受理
智通财经 · 03-03
智飞生物(300122.SZ)：德谷胰岛素注射液申请生产注册获受理
智飞生物：截至2026年2月13日，公司普通股股东人数为125,740
证券之星 · 02-28
智飞生物：截至2026年2月13日，公司普通股股东人数为125,740
智飞生物(300122.SZ)：HK.3-JN.1新冠病毒mRNA疫苗获临床试验批准
智通财经 · 02-26
智飞生物(300122.SZ)：HK.3-JN.1新冠病毒mRNA疫苗获临床试验批准
智飞生物：截至2026年2月10日，公司普通股股东人数为126648
证券之星 · 02-14
智飞生物：截至2026年2月10日，公司普通股股东人数为126648
智飞生物：积极开展自主产品的国际注册、认证工作
证券之星 · 02-14
智飞生物：积极开展自主产品的国际注册、认证工作
智飞生物：截至2026年1月30日，公司普通股股东人数为128,281
证券之星 · 02-09
智飞生物：截至2026年1月30日，公司普通股股东人数为128,281
智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)获得临床试验批准
智通财经网 · 02-09
智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)获得临床试验批准
智飞生物最新公告：冻干水痘灭活疫苗获得临床试验批准通知书
证券之星 · 02-04
智飞生物最新公告：冻干水痘灭活疫苗获得临床试验批准通知书
智飞生物(300122.SZ)：带状疱疹mRNA疫苗获临床试验批准
智通财经 · 02-03
智飞生物(300122.SZ)：带状疱疹mRNA疫苗获临床试验批准
医保数据发布再升级；多家药企发布业绩预告
21世纪经济报道 · 02-02
医保数据发布再升级；多家药企发布业绩预告
智飞生物（300122）披露冻干乙型脑炎灭活疫苗临床试验申请获受理公告，1月30日股价下跌3.45%
证券之星 · 01-30
智飞生物（300122）披露冻干乙型脑炎灭活疫苗临床试验申请获受理公告，1月30日股价下跌3.45%
智飞生物：人二倍体狂犬病疫苗等处于上市审评阶段
证券之星 · 01-30
智飞生物：人二倍体狂犬病疫苗等处于上市审评阶段
智飞生物：贯彻“技术&市场”双轮驱动的发展战略
证券之星 · 01-29
智飞生物：贯彻“技术&市场”双轮驱动的发展战略
加载更多
公司概况
公司名称：
重庆智飞生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2010-09-28
主营业务：
重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是预防流脑疫苗、宫颈癌疫苗、肺炎疫苗、流感疫苗、轮状病疫苗。
发行价格：
37.98
{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":15.66,"timestamp":1773990183000,"preClose":15.9,"halted":0,"volume":16172453,"delay":0,"changeRate":-0.0151,"floatShares":1414000000,"shares":2394000000,"eps":-0.5592,"marketStatus":"已收盘","change":-0.24,"latestTime":"03-20 15:00:00","open":15.95,"high":16.2,"low":15.61,"amount":256000000,"amplitude":0.0371,"askPrice":15.67,"askSize":157,"bidPrice":15.66,"bidSize":140,"shortable":0,"etf":0,"ttmEps":-0.5592,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774229400000},"marketStatusCode":5,"adr":0,"adjPreClose":15.9,"symbolType":"stock","openAndCloseTimeList":[[1773970200000,1773977400000],[1773982800000,1773990000000]],"highLimit":17.49,"lowLimit":14.31,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"isCdr":false,"pbRate":1.3,"roa":"--","roe":"--","epsLYR":0.8427,"committee":0.128012,"marketValue":37487000000,"turnoverRate":0.0114,"status":1,"floatMarketCap":22148000000},"requestUrl":"/m/hq/s/300122","defaultTab":"news","newsList":[{"id":"2620789640","title":"智飞生物：公司与中山大学、中山大学肿瘤防治中心就EB病毒候选疫苗产品的开发达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2620789640","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620789640?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:45","pubTimestamp":1773996325,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)03月20日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问贵公司有没有鼻咽癌EB病毒疫苗的技术储备？智飞生物回复：您好，公司与中山大学、中山大学肿瘤防治中心就EB病毒候选疫苗产品的开发达成合作，并获得相关发明专利。EBV疫苗处于临床前研发阶段，详情请关注公司的信息披露。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000028530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0046","159646","BK0239","LU1328615791.USD","BK0196","LU2148510915.USD","LU2580892862.HKD","LU1064131003.USD","BK0188","300122","BK0077","LU2580892789.USD"],"gpt_icon":0},{"id":"2620374475","title":"智飞生物（300122）披露控股股东部分股份质押公告，3月17日股价下跌0.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620374475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620374475?lang=zh_cn&edition=full","pubTime":"2026-03-17 22:35","pubTimestamp":1773758115,"startTime":"0","endTime":"0","summary":"截至2026年3月17日收盘，智飞生物报收于16.28元，较前一交易日下跌0.73%，最新总市值为389.71亿元。公司于2026年3月17日披露《关于公司控股股东部分股份质押的公告》。公告显示，公司控股股东、实际控制人蒋仁生先生将其持有的20,100,000股公司股份进行质押，占其所持股份比例1.73%，占公司总股本比例0.84%，质押用途为股权类投资，质权人为重庆农村商业银行股份有限公司。蒋仁生及其一致行动人合计持股1,305,973,500股，本次质押后累计质押股份占公司总股本5.82%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700042187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","LU2148510915.USD","BK0046","LU1064130708.USD","300122","BK0196","LU2580892789.USD","BK0077","LU2580892862.HKD","LU1064131003.USD","BK0239","BK0188"],"gpt_icon":0},{"id":"2619453248","title":"智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619453248","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619453248?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:33","pubTimestamp":1773650038,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)公告，公司近日收到全资子公司安徽智飞龙科马生物制药有限公司(简称“智飞龙科马”)报告，由智飞龙科马自主研发的改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗获得国家药品监督管理局药物临床试验批准通知书，同意本品在18周岁及以上人群中开展预防猴痘病毒引起的猴痘疾病的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗获临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1328615791.USD","LU2148510915.USD","BK0046","LU1064130708.USD","300122","BK0196","LU2580892789.USD","BK0077","LU2580892862.HKD","LU1064131003.USD","BK0239","BK0188"],"gpt_icon":0},{"id":"2619160996","title":"智飞生物：截至2026年3月10日，公司普通股股东人数为123603","url":"https://stock-news.laohu8.com/highlight/detail?id=2619160996","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619160996?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:12","pubTimestamp":1773393141,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)03月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止3月10日公司股东人数是多少？谢谢智飞生物回复：您好，截至2026年3月10日，公司普通股股东人数为123603，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300028952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","BK0077","BK0188","BK0239","LU2580892789.USD","LU2580892862.HKD","LU1328615791.USD","LU1064131003.USD","LU2148510915.USD","BK0046","LU1064130708.USD","BK0196"],"gpt_icon":0},{"id":"2619607160","title":"智飞生物：宸安生物的司美格鲁肽注射液（减重）已完成临床III期患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2619607160","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619607160?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:12","pubTimestamp":1773393136,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)03月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，子公司宸安生物的司美格鲁肽注射液（减重）已进入临床III期试验阶段，是公司战略布局GLP-1及胰岛素药物管线的关键一步。目前进展如何？此药上市之后，与同款药品相比其最大竞争力是什么？在价格上是否比国外同类进口产品有更大优势？智飞生物回复：您好，宸安生物的司美格鲁肽注射液（减重）已完成临床III期患者入组，公司的研发管线及其进展请持续关注公司的信息披露，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300028946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","300122","BK0046","BK0196","BK0239","LU2148510915.USD","BK0188","LU1328615791.USD","LU1064131003.USD","LU2580892789.USD","LU2580892862.HKD","BK0077"],"gpt_icon":0},{"id":"2617968750","title":"“真金白银”显诚意：代表委员热议如何增强投资者“获得感”","url":"https://stock-news.laohu8.com/highlight/detail?id=2617968750","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617968750?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:07","pubTimestamp":1772798828,"startTime":"0","endTime":"0","summary":"“投资与回报是资本市场的一体两面，我们将进一步完善上市公司分红激励约束机制，推动绩优公司结合实际出台中期分红、增加分红频次，提升投资者获得感。”3月6日下午，中国证监会主席吴清在十四届全国人大四次会议经济主题记者会上的这番讲话，迅速在两会代表委员中引发热议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603063664703183.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603063664703183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK4547","002330","300433","BK4535","301033","300769","000723","300607","002230","002216","300666","300122","BK4588","000630","06613"],"gpt_icon":0},{"id":"2617343685","title":"智飞生物：人二倍体狂犬病疫苗、15价肺炎结合疫苗、四价流脑结合疫苗、利拉鲁肽注射液、德谷胰岛素注射液处于申报上市阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2617343685","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617343685?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:51","pubTimestamp":1772787077,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物03月06日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价连跌了6年，近期又创新低。公司一直将代理国外疫苗作为主要收入来源，公司没有自己的产品，而代理的国外疫苗营收大幅减少且开始巨额亏损。目前，公司人二倍体狂犬病疫苗、15价肺炎结合疫苗、四价流脑结合疫苗、利拉鲁肽注射液、德谷胰岛素注射液处于申报上市阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600026730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU1328615791.USD","BK0188","LU2148510915.USD","BK0239","LU1064131003.USD","BK0077","159646","300122","LU2580892862.HKD","LU2580892789.USD","LU1064130708.USD","BK0046"],"gpt_icon":0},{"id":"2616312818","title":"智飞生物(300122.SZ)：德谷胰岛素注射液申请生产注册获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2616312818","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616312818?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:22","pubTimestamp":1772526146,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)公告，由控股子公司重庆宸安生物制药有限公司(简称“宸安生物”)研发的德谷胰岛素注射液申请生产注册获得国家药品监督管理局出具的《受理通知书》。公告显示，德谷胰岛素为长效胰岛素类似物，凭借独特的分子结构与作用机制，可在皮下形成可溶性多六聚体储库，实现平稳、持续、缓慢释放胰岛素，作用时间显著延长，具有降糖效果平稳、血糖变异性小、低血糖风险低、安全性良好、给药时间灵活等优点，每日一次皮下注射，适用于成人2型糖尿病治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：德谷胰岛素注射液申请生产注册获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2580892789.USD","BK0196","LU2148510915.USD","BK0046","LU1328615791.USD","300122","BK0077","BK0239","LU2580892862.HKD","LU1064130708.USD","BK0188","LU1064131003.USD"],"gpt_icon":0},{"id":"2614138148","title":"智飞生物：截至2026年2月13日，公司普通股股东人数为125,740","url":"https://stock-news.laohu8.com/highlight/detail?id=2614138148","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614138148?lang=zh_cn&edition=full","pubTime":"2026-02-28 16:12","pubTimestamp":1772266327,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)02月28日在投资者关系平台上答复投资者关心的问题。投资者提问：请问最新一期公司的股东人数是多少？智飞生物回复：您好，截至2026年2月13日，公司普通股股东人数为125,740，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022800009005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","LU2148510915.USD","BK0046","LU1064130708.USD","300122","BK0196","LU2580892789.USD","BK0077","LU2580892862.HKD","LU1064131003.USD","BK0239","BK0188"],"gpt_icon":0},{"id":"2614090899","title":"智飞生物(300122.SZ)：HK.3-JN.1新冠病毒mRNA疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2614090899","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614090899?lang=zh_cn&edition=full","pubTime":"2026-02-26 15:46","pubTimestamp":1772091974,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)公告，公司近日收到全资子公司安徽智飞龙科马生物制药有限公司报告，由智飞龙科马自主研发的HK.3-JN.1新型冠状病毒mRNA疫苗获得国家药品监督管理局药物临床试验批准通知书，同意本品开展预防新型冠状病毒感染所致疾病的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：HK.3-JN.1新冠病毒mRNA疫苗获临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2580892862.HKD","LU2580892789.USD","BK0239","159646","LU1064130708.USD","LU1064131003.USD","BK0196","BK0077","LU1328615791.USD","BK0046","BK0188","LU2148510915.USD","300122"],"gpt_icon":0},{"id":"2611164891","title":"智飞生物：截至2026年2月10日，公司普通股股东人数为126648","url":"https://stock-news.laohu8.com/highlight/detail?id=2611164891","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611164891?lang=zh_cn&edition=full","pubTime":"2026-02-14 16:06","pubTimestamp":1771056367,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)02月14日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好，请问截止至2026年2月10日收盘公司股东人数为多少，谢谢！智飞生物回复：您好，截至2026年2月10日，公司普通股股东人数为126648，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021400011007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","BK0077","BK0188","BK0239","LU2580892789.USD","LU2580892862.HKD","LU1328615791.USD","LU1064131003.USD","LU2148510915.USD","BK0046","LU1064130708.USD","BK0196"],"gpt_icon":0},{"id":"2611116149","title":"智飞生物：积极开展自主产品的国际注册、认证工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2611116149","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611116149?lang=zh_cn&edition=full","pubTime":"2026-02-14 16:03","pubTimestamp":1771056188,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)02月14日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在糖尿病GLP-1，减重药司美格鲁肽，癌症罕见病上的业务能力日益增强，将来是否具备与全球医药巨头相关业务的一争之力，从而更有利的拓展海外市场？智飞生物回复：您好，公司积极开展自主产品的国际注册、认证工作，针对未满足的临床需求提供创新产品，切实提升疫苗、治疗性产品的可及性、可担负性。公司海外的销售收入请持续关注公司的定期报告。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021400010870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","BK0196","300122","LU1064131003.USD","BK0188","BK0077","LU2580892789.USD","LU1064130708.USD","LU2148510915.USD","BK0239","LU2580892862.HKD","BK0046"],"gpt_icon":0},{"id":"2610636399","title":"智飞生物：截至2026年1月30日，公司普通股股东人数为128,281","url":"https://stock-news.laohu8.com/highlight/detail?id=2610636399","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610636399?lang=zh_cn&edition=full","pubTime":"2026-02-09 17:57","pubTimestamp":1770631027,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)02月09日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好！截止1月30号，股东人数多少智飞生物回复：您好，截至2026年1月30日，公司普通股股东人数为128,281，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900023339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU2580892862.HKD","LU2580892789.USD","LU2148510915.USD","300122","BK0046","BK0077","BK0196","LU1064130708.USD","BK0188","BK0239","LU1328615791.USD"],"gpt_icon":0},{"id":"2610633634","title":"智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2610633634","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610633634?lang=zh_cn&edition=full","pubTime":"2026-02-09 17:12","pubTimestamp":1770628370,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物 发布公告，公司于近日获悉，由全资子公司安徽智飞龙科马生物制药有限公司研发的重组带状疱疹ZFA01佐剂疫苗获得国家药品监督管理局药物临床试验批准通知书，同意在40岁及以上人群中开展预防带状疱疹的临床试验。公司的重组带状疱疹ZFA01佐剂疫苗采用自主研制的新型佐剂，可同时激发细胞免疫与体液免疫反应，免疫应答更为全面，有望增强疫苗的保护效果。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)获得临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2148510915.USD","BK0077","300122","LU2580892862.HKD","LU1328615791.USD","LU2580892789.USD","LU1064130708.USD","159646","BK0188","BK0196","BK0239","BK0046","LU1064131003.USD"],"gpt_icon":0},{"id":"2608359903","title":"智飞生物最新公告：冻干水痘灭活疫苗获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2608359903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608359903?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:41","pubTimestamp":1770194465,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告称，公司全资子公司智飞龙科马研发的冻干水痘灭活疫苗获得国家药品监督管理局药物临床试验批准通知书，同意开展预防水痘-带状疱疹病毒感染引起的水痘的临床试验。该疫苗采用创新灭活技术路线，生产用细胞株、毒株均为公司自主研发。目前国内有8款水痘减毒活疫苗获批上市使用，但暂无水痘灭活疫苗正式获批上市，市场前景广阔。该临床试验申请获得批准对公司近期业绩不会产生重大影响，但有利于公司夯实研发技术，加强在研管线储备。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400027715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892789.USD","BK0196","LU2148510915.USD","BK0046","LU1328615791.USD","300122","BK0077","BK0239","LU2580892862.HKD","LU1064130708.USD","BK0188","LU1064131003.USD"],"gpt_icon":0},{"id":"2608823578","title":"智飞生物(300122.SZ)：带状疱疹mRNA疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2608823578","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608823578?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:05","pubTimestamp":1770105905,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)公告，公司子公司安徽智飞龙科马生物制药有限公司(简称“智飞龙科马”)研发的带状疱疹mRNA疫苗获得国家药品监督管理局药物临床试验批准通知书，同意开展用于预防带状疱疹的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：带状疱疹mRNA疫苗获临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","LU2580892862.HKD","159646","LU1328615791.USD","LU1064130708.USD","300122","BK0077","BK0188","BK0046","LU2580892789.USD","BK0239","BK0196","LU1064131003.USD"],"gpt_icon":0},{"id":"2608887409","title":"医保数据发布再升级；多家药企发布业绩预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2608887409","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608887409?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:04","pubTimestamp":1769990666,"startTime":"0","endTime":"0","summary":"政策动向医保数据发布再升级2月1日，国家医保局官微发文称，医保数据工作组是医保部门的一项创新性工作。数据发布活动组织一年多以来，各地发布内容不断丰富，发布形式更加多样，一些地方基于按病种付费改革开展病种专题分析，为疾病诊疗资源消耗“画像”，为医疗机构提供更加具体、好用的管理工具。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638025174.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638025174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1223082196.USD","LU2328871848.SGD","LU2148510915.USD","LU2580892789.USD","BK0046","CDE","09995","LU1328615791.USD","BK0028","BK1161","LU1969619763.USD","LU1064131003.USD","BK0239","BK0077","BK0196","000661","LU1064130708.USD","BK1574","LU1223082519.USD","LU1223083913.SGD","BK4017","300122","688331","BK0057","BK0188","BK1583","LU2580892862.HKD","688506","LU2488822045.USD","BK0075"],"gpt_icon":0},{"id":"2607804924","title":"智飞生物（300122）披露冻干乙型脑炎灭活疫苗临床试验申请获受理公告，1月30日股价下跌3.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607804924","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607804924?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:14","pubTimestamp":1769782462,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，智飞生物报收于17.37元，较前一交易日下跌3.45%，最新总市值为415.8亿元。该股当日开盘17.83元，最高17.93元，最低17.36元，成交额达5.3亿元，换手率为2.13%。智飞生物当日发布公告称，公司全资子公司安徽智飞龙科马生物制药有限公司研发的冻干乙型脑炎灭活疫苗临床试验申请获得国家药品监督管理局受理，受理号为CXSL2600147。该疫苗采用人二倍体细胞制备，具有较高的安全性。目前国内市场尚无同类技术生产的乙型脑炎灭活疫苗获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","LU2148510915.USD","BK0046","LU1064130708.USD","300122","BK0196","LU2580892789.USD","BK0077","LU2580892862.HKD","LU1064131003.USD","BK0239","BK0188"],"gpt_icon":0},{"id":"2607097751","title":"智飞生物：人二倍体狂犬病疫苗等处于上市审评阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2607097751","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607097751?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:30","pubTimestamp":1769761839,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物01月30日在投资者关系平台上答复投资者关心的问题。公司高度重视研发创新，形成智飞绿竹、智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局，实现“预防&治疗”协同发展。目前人二倍体狂犬病疫苗、四价流脑结合疫苗、15价肺炎结合疫苗及利拉鲁肽注射液处于上市审评阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000027678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU2580892789.USD","BK0188","LU2580892862.HKD","159646","BK0046","BK0196","LU1064131003.USD","LU1064130708.USD","BK0239","BK0077","300122","LU1328615791.USD"],"gpt_icon":0},{"id":"2607082777","title":"智飞生物：贯彻“技术&市场”双轮驱动的发展战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2607082777","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607082777?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:51","pubTimestamp":1769691091,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)01月28日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好请问公司未来的发展目标是什么？智飞生物回复：您好，公司贯彻“技术&市场”双轮驱动的发展战略，依托智飞绿竹、智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局，实现“预防&治疗”协同发展。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900040873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","LU2580892789.USD","LU2148510915.USD","LU2580892862.HKD","LU1064131003.USD","BK0196","BK0077","LU1328615791.USD","LU1064130708.USD","BK0188","300122"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774017845141,"stockEarnings":[{"period":"1week","weight":-0.0381},{"period":"1month","weight":-0.0592},{"period":"3month","weight":-0.1774},{"period":"6month","weight":-0.2753},{"period":"1year","weight":-0.3772},{"period":"ytd","weight":-0.1574}],"compareEarnings":[{"period":"1week","weight":-0.0297},{"period":"1month","weight":-0.0185},{"period":"3month","weight":0.0298},{"period":"6month","weight":0.0488},{"period":"1year","weight":0.1693},{"period":"ytd","weight":0.0095}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"123603人(较上一季度减少1.48%)","perCapita":"11442股","listingDate":"2010-09-28","address":"重庆市两江新区庆云路1号50层","registeredCapital":"239378万元","survey":" 重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是预防流脑疫苗、宫颈癌疫苗、肺炎疫苗、流感疫苗、轮状病疫苗。","listedPrice":37.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}